Objectives of iron chelation therapy in myelodysplastic syndromes: More than meets the eye?

Blood

Volumn 114, Issue 26, 2009, Pages 5251-5255

  Pullarkat, Vinod ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; HEART DISEASE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION RISK; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SURVIVAL; TREATMENT OUTCOME; ANIMAL; CHELATION THERAPY; CLINICAL TRIAL;

IRON; IRON CHELATING AGENT;

ANIMALS; CHELATION THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES;

EID: 73149086083     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-234062     Document Type: Review

References (50)

1. List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes (MDS) [abstract]. Blood. 2008;112(11):634a.
2. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603.
3. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78(6):487-494.
4. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 2009;25(1):139-147.
5. DeLoughery TG. Iron: the fifth horseman of the apocalypse? Am J Hematol. 2009;84(5):263-264.
6. Steensma DP. Myelodysplasia paranoia: iron as the new radon. Leuk Res. 2009;33(9):1158-1163.
7. Cortelezzi A, Cattaneo C, Cristiani S, et al. Nontransferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis. Hematol J. 2000;1(3):153-158.
8. Ganz T, Nemeth E. Regulation of iron acquisition and iron distribution in mammals. Biochimica et Biophysica Acta. 2006;1763(7):690-699.
9. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093.
10. Winder A, Lefkowitz R, Ghoti H, et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol. 2008;142(4):669-671.
11. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-1101.
12. Breda L, Ghoti H, Rivella S, et al. Expression of genes regulating iron metabolism in hepatocyte cell-line HepG2 induced by sera from MDS patients [abstract]. Blood. 2007;110(11):4612a.
13. Malcovati L, Della Porta MG, Laarakkers CM, et al. Erythroid activity, transfusion iron overload and hepcidin levels in patients with myelodysplastic syndrome [abstract]. Blood. 2008;112(11): 2676a.
14. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-Labile plasma iron in iron overload. Best Practice Res Clin Hematol. 2005;18(2):277-287.
15. Esposito B, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102(7): 2670-2677.
16. Sahlstedt L, Ebeling F, Bonsdorff L, Parkinnen J, Ruutu T. Non transferring-bound iron during allogeneic stem cell transplantation. Br J Haematol. 2001;113(3):836-838.
17. Durken M, Nielsen P, Knobel S, et al. Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. Free Radical Biol Med. 1997;22(7):1159-1163.
18. Bradley SJ, Gosriwitana I, Srichairatanakool S, Hider RC, Porter JB. Non transferring-bound iron induced by myeloablative chemotherapy. Br J Haematol. 1997;99(2):337-343.
19. Porter JB, Cappellini MD, El-Beshlawy A, et al. Effect of deferasirox (Exjade) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemia enrolled in the large-scale, prospective 1-year EPIC trial [abstract]. Blood. 2008;112(11):3881a.
20. Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol. 2007;79(6):463-467.
21. Rachmilewitz E, Merkel D, Ghoti H, et al. Improvement in oxidative stress parameters in MDS patients with iron overload treated with deferasirox [abstract]. Blood. 2008;112(11):2675a.
22. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31(suppl 3):S2-S6.
23. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med. 1971;51(2): 209-221.
24. Konen E, Ghoti H, Goitein O, et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol. 2007;82(11):1013-1016.
25. Di Tucci AA, Matta G, Deplano S, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica. 2008;93(9):1385-1388.
26. Chacko J, Pennell DJ, Tanner MA, et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007;138(5):587-593.
27. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with defferoxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101(11):4632-4639.
28. Bullen JJ, Rogers HJ, Spadling PB, Ward CG. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol. 2006;55(pt 3):251-258.
29. Caroline L, Rosner F, Kozinn PJ. Elevated serum iron, low unbound transferrin and candidiasis in acute leukemia. Blood. 1969;34(4):441-451.
30. Karp JE, Merz WG. Association of reduced total iron binding capacity and fungal infections in leukemic granulocytic patients. J Clin Oncol. 1986; 4(2):216-220.
31. von Bonsdorff L, Sahlstedt L, Ebeling F, Ruutu T, Parkkinen J. Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. FEMS Immunol Med Microbiol. 2003; 37(1):45-51.
32. Halliwell B, Aruoma OI, Mufti G, Bomford A. Bleomycin-detectable iron in serum from leukemic atients before and after chemotherapy. FEBS Lett. 1988;241(1-2):202-204.
33. Boelaert JR, de Locht M, van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore mediated infection: in vitro and in vivo animal studies. J Clin Invest. 1993;91(5):1979-1986.
34. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogeneisis and treatment. Curr Opin Infect Dis. 2008;21(6):620-625.
35. Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2008;42(12):799-805.
36. Platzbecker U, Bornhauser M, Germing U, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant. 2008;14(11):1217-1225.
37. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplant serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-4588.
38. Mahindra A, Bolwell B, Sobecks R, et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic hematopoietic stem cell transplantation. Br J Haematol. 2009;146(3):310-316.
39. Mahindra A, Sobecks R, Rybicki L, et al. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation [letter]. Bone Marrow Transplant. Prepublished on April 20, 2009 as DOI 10.1038/bmt.2009.77.
40. Maradei SC, Maiolino A, Mello de Azevedo A, Colares M, Bouzas LF, Nucci M. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood. 2009;114(6): 1270-1275.
41. Altes A, Remacha AF, Sarda P, et al. Frequent severe iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant. 2004;34(6): 505-509.
42. Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007;110(6):1303-1306.
43. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of 5 cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24(3):307-312.
44. Naka K, Muraguchi T, Hoshii T, Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal. 2008;10(11):1883-1894.
45. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle. 2007;6(16):1982-1994.
46. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood. 2008;112(11):640a.
47. Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients: a prospective analysis by the GFM [abstract]. Blood. 2007; 110(11):249a.
48. Leitch, HA, Wong DHC, Leger CS, et al. Improved leukemia-free and overall survival in patients with myelodysplastic syndromes recieving iron chelation therapy: a subgroup analysis [abstract]. Blood. 2007;110(11):1469a.
49. Messa E, Defilippi I, Roetto A, et al. Deferasirox is the only iron chelator acting as a potent NF-KB inhibitor in myelodysplastic syndromes [abstract]. Blood. 2008;112(11):2671a.
50. Hartmann J, Sinzig U, Wulf G, et al. Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS [abstract]. Blood. 2008;112(11):2694a.